trending Market Intelligence /marketintelligence/en/news-insights/trending/vcwwckeuuhy82avjwugfea2 content esgSubNav
In This List

Impax shareholders approve merger with Amneal Pharmaceuticals

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Impax shareholders approve merger with Amneal Pharmaceuticals

Impax Laboratories Inc.'s stockholders approved the company's merger with Amneal Pharmaceuticals LLC.

The shareholder approval was one of the requirements for the closing of the deal, which is expected to occur during the second quarter.

The closing of the transaction remains subject to certain regulatory approvals and satisfaction of customary closing conditions.

Impax and Amneal are merging in an all-stock transaction, in which Amneal Holdings members will own about 75% of the new company's shares and Impax shareholders will own about 25%.

The combined company will be called Amneal Pharmaceuticals Inc.